More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Influenza A virus PA protein antibody

Influenza A virus PA protein antibody

GTX118991
GeneTex
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
ReactivityVirus
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    GeneTex
  • Product Name
    Influenza A virus PA protein antibody
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:100-1:1000. ICC/IF: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoFluorescence, Western Blot, ImmunoCytoChemistry
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1.21 mg/ml
  • Conjugate
    Unconjugated
  • Host
    Rabbit
  • Isotype
    IgG
  • Reactivity
    Virus
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Sheppard CM, Goldhill DH, Swann OC, et al. An Influenza A virus can evolve to use human ANP32E through altering polymerase dimerization. Nat Commun. 2023,14(1):6135. doi: 10.1038/s41467-023-41308-4
    Read this paper
  • Han YJ, Lee KM, Wu GH, et al. Targeting influenza A virus by splicing inhibitor herboxidiene reveals the importance of subtype-specific signatures around splice sites. J Biomed Sci. 2023,30(1):10. doi: 10.1186/s12929-023-00897-4
    Read this paper
  • Li Q, Jiang Z, Ren S, et al. SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. Adv Sci (Weinh). 2022,9(34):e2203088. doi: 10.1002/advs.202203088
    Read this paper
  • Fernbach S, Spieler EE, Busnadiego I, et al. Restriction factor screening identifies RABGAP1L-mediated disruption of endocytosis as a host antiviral defense. Cell Rep. 2022,38(12):110549. doi: 10.1016/j.celrep.2022.110549
    Read this paper
  • Sun H, Li X, Chen M, et al. Multi-Omics-Guided Discovery of Omicsynins Produced by Streptomyces sp. 1647: Pseudo-Tetrapeptides Active Against Influenza A Viruses and Coronavirus HCoV-229E. Engineering (Beijing). 2022,16:176-186. doi: 10.1016/j.eng.2021.05.010
    Read this paper
  • Ma C, Li Y, Zong Y, et al. p21 restricts influenza A virus by perturbing the viral polymerase complex and upregulating type I interferon signaling. PLoS Pathog. 2022,18(2):e1010295. doi: 10.1371/journal.ppat.1010295
    Read this paper
  • Bdeir N, Arora P, Gärtner S, et al. Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity. Sci Rep. 2021,11(1):20477. doi: 10.1038/s41598-021-99691-1
    Read this paper
  • Liu X, Xu F, Ren L, et al. MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes. Nat Commun. 2021,12(1):4427. doi: 10.1038/s41467-021-24724-2
    Read this paper
  • Kwon EB, Yang HJ, Kim YS, et al. 8-O-(E-p-methoxycinnamoyl)harpagide Inhibits Influenza A Virus Infection by Suppressing Intracellular Calcium. Molecules. 2021,26(4). doi: 10.3390/molecules26041029
    Read this paper
  • Gong W, He X, Huang K, et al. Interaction of NEP with G Protein Pathway Suppressor 2 Facilitates Influenza A Virus Replication by Weakening the Inhibition of GPS2 to RNA Synthesis and Ribonucleoprotein Assembly. J Virol. 2021,95(10):pii: JVI.00008-21. doi: 10.1128/JVI.00008-21.
    Read this paper

Datasheet

Download Datasheet

FAQ

Go to our frequently asked questions